INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
Search

All disclosures

Every ingested record across SEC Form 4, 13F, House PTRs and Robinhood Chain, searchable by ticker, name or wallet address.

Results

Data sources
SEC Form 41h ago
House PTR1h ago
SEC 13F1h ago
Robinhood Chain1h ago

Results

78,999 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
WA
Ware J. AnthonyDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
10.6K sh
Apr 20, 2026Apr 22, 2026
Page 1138 of 1975
← PrevNext →
traded Apr 20, 2026
+2d
SEC Form 4

Evidence

9
LF
Lizzul Paul F.Chief Medical Officer
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
21.1K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC Form 4

Evidence

9
WA
Ware J. AnthonyDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
5,500 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC Form 4

Evidence

9
FD
Faga DanielDirector, President, CEO
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
194.9K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC Form 4

Evidence

9
SD
Stephenson DaveDirector
LYFTLyft, Inc.
Grant or award
A—
1,127 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC Form 4

Evidence

9
HJ
Humes JenniferChief Accounting Officer
ROIVRoivant Sciences Ltd.
Grant or award
A—
27.2K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC Form 4

Evidence

9
FD
Faga DanielDirector, President, CEO
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
17.9K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC Form 4

Evidence

8
OC
O'Hara John CharlesDirector, Chief Financial Officer
LAESSEALSQ Corp
Open-market sale · 10b5-1 plan
SELL$30K
10.0K sh
Apr 21, 2026Apr 22, 2026
traded Apr 21, 2026
+1dSEC Form 4

Evidence

8
OC
O'Hara John CharlesDirector, Chief Financial Officer
LAESSEALSQ Corp
Open-market sale · 10b5-1 plan
SELL$28K
10.0K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC Form 4

Evidence

8
JR
Jeffrey John Ronald Jr.Director
AGXARGAN INC
Option exercise
M$174K
4,698 sh
Apr 21, 2026Apr 22, 2026
traded Apr 21, 2026
+1dSEC Form 4

Evidence

8
CE
Collins Charles Edwin IVCHIEF EXECUTIVE OFFICER, GEMMA
AGXARGAN INC
Option exercise
M$177K
5,235 sh
Apr 21, 2026Apr 22, 2026
traded Apr 21, 2026
+1dSEC Form 4

Evidence

6
CS
Cross ShawnChief Financial Officer
PCRXPacira BioSciences, Inc.
Option exercise · 10b5-1 plan
M$127K
7,714 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC Form 4

Evidence

6
FA
Fang AndyDirector
DASHDoorDash, Inc.
Grant or award
A—
4,869 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC Form 4

Evidence

6
TS
Tang StanleyDirector
DASHDoorDash, Inc.
Grant or award
A—
3,124 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC Form 4

Evidence

6
KP
Kirol Charles PeterChief Operating Officer
PTONPELOTON INTERACTIVE, INC.
Open-market sale · 10b5-1 plan
SELL$19K
3,670 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC Form 4

Evidence

5
FD
Feldman Jason D.SVP, IR, Treasury & Tax
CRCrane Co
Tax withholding
F$16K
83 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC Form 4

Evidence

5
SH
Sehmi HarminderChief Financial Officer
BZAIBlaize Holdings, Inc.
Option exercise · 10b5-1 plan
M$288K
505.1K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC Form 4

Evidence

5
SS
Skates SpenserDirector, CEO and President, 10% Owner
AMPLAmplitude, Inc.
Grant or award
A—
1.32M sh
Apr 21, 2026Apr 22, 2026
traded Apr 21, 2026
+1dSEC Form 4

Evidence

5
CE
Collins Charles Edwin IVCHIEF EXECUTIVE OFFICER, GEMMA
AGXARGAN INC
Option exercise
M$50K
333 sh
Apr 21, 2026Apr 22, 2026
traded Apr 21, 2026
+1dSEC Form 4

Evidence

5
FD
Feldman Jason D.SVP, IR, Treasury & Tax
CRCrane Co
Option exercise
M—
162 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC Form 4

Evidence

5
CE
Collins Charles Edwin IVCHIEF EXECUTIVE OFFICER, GEMMA
AGXARGAN INC
Option exercise
M$31K
500 sh
Apr 21, 2026Apr 22, 2026
traded Apr 21, 2026
+1dSEC Form 4

Evidence

4
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Derivative conversion · 10b5-1 plan
C—
200.0K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC Form 4

Evidence

4
CS
Cross ShawnChief Financial Officer
PCRXPacira BioSciences, Inc.
Open-market sale · 10b5-1 plan
SELL$71K
2,845 sh
Apr 21, 2026Apr 22, 2026
traded Apr 21, 2026
+1dSEC Form 4

Evidence

3
HI
Hyep IvanChief Financial Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M—
9,200 sh
Apr 21, 2026Apr 22, 2026
traded Apr 21, 2026
+1dSEC Form 4

Evidence

2
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Grant or award
A—
194.9K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC Form 4

Evidence

2
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Disposition to issuer
D—
379.6K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC Form 4

Evidence

2
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Grant or award
A—
2,321 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC Form 4

Evidence

2
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Disposition to issuer
D—
305.5K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC Form 4

Evidence

2
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Disposition to issuer
D—
133.4K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC Form 4

Evidence

2
KA
Kuykendall AnneSVP and Chief Legal Officer
PENGPenguin Solutions, Inc.
Tax withholding · 10b5-1 plan
F$82K
3,062 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC Form 4

Evidence

2
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Disposition to issuer
D—
9,200 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC Form 4

Evidence

2
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Grant or award
A—
133.4K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC Form 4

Evidence

2
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Grant or award
A—
379.6K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC Form 4

Evidence

2
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Grant or award
A—
11.0K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC Form 4

Evidence

2
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Grant or award
A—
9,200 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC Form 4

Evidence

2
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Disposition to issuer
D—
194.9K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC Form 4

Evidence

2
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Disposition to issuer
D—
2,321 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC Form 4

Evidence

2
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Grant or award
A—
305.5K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC Form 4

Evidence

1
FL
Freemen-Bosworth LaurenEVP/Gen Counsel & Corp Sec
PBIPITNEY BOWES INC /DE/
Open-market sale · 10b5-1 plan
SELL$2,408
169 sh
Apr 21, 2026Apr 22, 2026
traded Apr 21, 2026
+1dSEC Form 4

Evidence

1
CS
Cross ShawnChief Financial Officer
PCRXPacira BioSciences, Inc.
Open-market sale · 10b5-1 plan
SELL$38K
1,500 sh
Apr 22, 2026Apr 22, 2026
traded Apr 22, 2026
+0dSEC Form 4

Evidence